Background: Dilated cardiomyopathy (DCM) is the most common cardiomyopathy with a common presentation of heart failure. It has been reported that CASZ1 loss‐of‐function mutation contributes to familial DCM and congenital ventricular septal defect (VSD). To date, only two pathogenic variants in CASZ1 have been previously reported worldwide.Methods: To identify the causative variant in an 11‐month‐old Chinese boy with DCM and left ventricular noncompaction cardiomyopathy (LVNC), trio‐whole‐exome sequencing was performed followed by mutational analysis and Sanger sequencing.Results: An unreported de novo heterozygous frameshift variant (c.2443_2459delGTGGGCACCCCCAGCCT, p.Val815Profs*14) in CASZ1 was idenitified in the proband. The frameshift mutation in CASZ1 not only led to DCM but also presented an LVNC phenotype.Conclusion: We have identified a novel CASZ1 variant in a patient with combined DCM and LVNC for the first time, thus broadening the phenotypic spectrum of CASZ1 variants. Furthermore, this study emphasized the usefulness of whole‐exome sequencing for genetic diagnosis of cardiomyopathy.
Genetic etiology in majority of patients with sporadic thoracic aortic aneurysm and dissections (STAAD) remains unknown. Recent GWAS study suggested common variant(s) in FBN1 is associated with STAAD. The present study aims to test this hypothesis and to identify mutation spectrum by targeted exome sequencing of the FBN1 gene in 146 unrelated patients with STAAD. Totally, 15.75% of FBN1 variants in STAAD were identified, including 5 disruptive and 18 missense mutations. Most of the variants were novel. Genotype-phenotype correlation analysis suggested that the maximum aortic diameter in the disruptive mutation group was significantly larger than that in the non-Cys missense mutation group. Interestingly, the variant Ala27Thr at −1 position, which is predicted to change the cleavage site of the signal peptidase of fibrillin-1, was detected in two unrelated patients. Furthermore, genotyping analysis of this variant detected 10 heterozygous Ala27Thr from additional 666 unrelated patients (1.50%), versus 7 from 1500 controls (0.47%), indicating a significant association of this variant with STAAD. Collectively, the identification of the variant Ala27Thr may represent a relatively common genetic predisposition and a novel pathogenetic mechanism for STAAD. Also, expansion of the mutation spectrum in FBN1 will be helpful in genetic counselling for Chinese patients with STAAD.
It has been shown that thoracic aortic aneurysm and dissection (TAAD) could be a Mendelian trait caused by a single gene mutation. The LOX gene mutation leads to the development of human TAAD. The LOXL4 gene is a member of the lysyl oxidase gene family. We identified seven variants in the LOXL4 gene in 219 unrelated patients with TAAD by whole-exome sequencing (WES). To further investigate whether LOXL4 is a candidate causative gene for human TAAD, a LOXL4 knockout mouse was generated, and the mutant mice were treated by subcutaneous infusion of angiotensin II. We found that abrogation of LOXL4 did not induce a more severe thoracic or abdominal aortic aneurysm compared with the wild-type C57BL/6J mice. Our results suggest that LOXL4 may not play a major role in the development of angiotensin II-induced aortic aneurysm. The functional study using this animal model system is important for the evaluation of candidate genes of TAAD identified by WES.
Abdominal aortic aneurysms (AAAs) are life-threatening due to the rupture of aorta. Different vascular cell types are known to be involved in AAA development. However, whether any specific cell cluster plays a critical role during AAA formation is unknown. Angiotensin II (Ang II) infused mouse AAA models are commonly used to study the development and progression of AAA. We here investigate the incidence of AAA at different ages or different doses of Ang II in C57BL/6J mice. There was no AAA formation at a concentration of 1.44 mg/kg/day or 2.16 mg/kg/day at the age of 14 weeks. At the age of 20 weeks and 32 weeks, the incidence of AAA was 18.2% (6/21) and 57.1% (4/7), respectively, with a concentration of 1.44 mg/kg/day. Using single-cell RNA sequencing, we found that increased clusters of monocytes and neutrophils, macrophages, T cells, and B cells were the typical changes in AAA. A special cluster transformed from endothelial cells (malignant ECs) was identified, in which genesinvolved in lipid metabolism, including Cd36, Lpl, Gpihbp1, Fabp4, and Pparg, were highly expressed. Mice receiving Ang II treatment without AAA development showed increased fibroblasts, which may prevent the occurrence of AAA. Through cell–cell interaction analysis, we found that the Cxcl12–Cxcr4/Ackr3 axis, which functions in inflammatory ligand– receptor binding, may play a role in AAA formation. Our results reveal that specific cell clusters may contribute to the progression or prevention of AAA formation. These findings provide new clues for the pathogenesis and intervention of AAA.